Room for daylight on medical device tax repeal? coverage of the medical device tax

Supporters of repealing a 2.3% levy on all U.S. sales of medical devices got a sliver of daylight this week after U.S. treasury secretary Jacob Lew said there might be room to revisit the tax.

"Maybe there’s a way of looking at it differently than the way it was designed," Lew told Sen. Kelly Ayotte (R-N.H.) during testimony before the Senate budget committee April 16.

Ayotte asked the treasury chief if President Barack Obama supported repealing the tax, citing a recent bipartisan but symbolic vote in the upper chamber to repeal the tax.

"There’s not much around here that we get 79 votes for in the Senate," Ayotte said. "I hope [Obama] would commit to working with both sides of the aisle on overturning this tax."

But Lew’s seeming willingness to revisit the tax came with some leavening.

"It’s always a dangerous business to reopen something when it’s a critical funding element in a complicated piece of legislation," he said. "We all agree that having the best technology available for our patients is a very high priority. It’s also important to note the dramatic increase in the cost associated with the reimbursement for these medical devices. … I would only point out that [the medical device industry] has been a very profitable business."

And in order to ditch the tax, a pay-for replacing the lost revenue would have to be found, Lew pointed out.

"It’s something that, if it were to be removed, it would have to be replaced," he said. "The idea was not to target startups. It has a much broader effect than that and many, if not most, of the sales are not [from] startups."

Responding to Lew’s Senate testimony, AdvaMed CEO Stephen Ubl sought to "clarify the facts regarding some of the issues you raised."

"First, it is important to understand that there has been no increase in reimbursement for medical technology relative to other health services. National spending on medical technology has remained essentially constant at 6% of national health expenditures for the last 2 decades. Moreover, because the industry is highly competitive, prices for medical technology have risen during the same period at an average annual rate of only 1% – less than a quarter the rate of other medical goods and services and less than half the rate of the overall CPI," Ubl wrote April 17.

Repealing the tax is "central to tax reform and economic growth," not a health policy issue, Ubl wrote.

"When enacted, the tax was used in a bookkeeping sense to offset some of the costs of the Affordable Care Act. Now, however, the tax is simply a part of general revenues. Repealing it will have no effect on the programs authorized under the Affordable Care Act," he wrote.

And the tax has a "highly uncompetitive impact" because it raises the total amount of federal taxes paid by U.S. medtech firms by 30%, Ubl claimed.

"When combined with the high and uncompetitive corporate tax rate already levied on American-based research & development and manufacturing, it is a profound disincentive against locating these activities in the U.S. – whether the manufacturer is a U.S. company or a U.S. subsidiary of a foreign company. That is directly contrary to the administration and our industry’s shared goal of keeping and growing good jobs in the U.S.," he wrote.

RSS From Medical Design & Outsourcing

  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]
  • Saelig introduces Multiple Instrument System MIS4 universal test system
    Saelig Company has introduced the ABI Electronics’ Multiple Instrument Station MIS4, an all-in-one testing tool that provides all commonly required test instruments in one compact programmable hardware module, mounted in a compact case or installed in a PC-drive bay. Controlled by ABI’s sophisticated SYSTEM 8 Ultimate PC software with a simple yet programmable operator interface, […]
  • AssurX announces document management software update for small to mid-size companies in FDA regulated industries
    AssurX, an enterprise quality management, risk and regulatory compliance solution provider, announces the release of the latest update to their AssurX document management software. The document management solution provides a cost-effective solution for small to medium sized companies faced with streamlined operations and is fully compliant for FDA regulated industries. Ideal solution for small to […]
  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]

Leave a Reply